it depends. Based on the past deals, the take over targets with approved drugs typically attract premium less than 100% because much of the gains has already been realised post FDA approval. For companies with mainly phase 2 or phase 3 pipelines, the premium is typically 100-200%. NEU would fall under the 2nd scenario and given the size and potential of the pipeline, I wouldn’t be surprised the premium is over 200% as the market has not yet fully appreciated the potential opportunity here
it depends. Based on the past deals, the take over targets with...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$23.11 |
Change
-0.860(3.59%) |
Mkt cap ! $2.951B | |||
| Open | High | Low | Value | Volume |
| $23.93 | $23.97 | $23.05 | $23.02M | 985.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5083 | $23.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $23.25 | 1026 | 2 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$23.22 |
Change
-0.860 ( 3.12 %) |
||||
| Open | High | Low | Volume | ||
| $23.81 | $23.94 | $23.05 | 198298 | ||
| Last updated 15.59pm 28/05/2024 ? | |||||
| NEU (ASX) Chart |